Biotie Therapies - Company Announcement

Biotie: Selincro launched in first European markets

BIOTIE THERAPIES CORP.     STOCK EXCHANGE RELEASE     22 April 2013 at 9:00 a.m.

Biotie: Selincro launched in first European markets

Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has started
launching Selincro(TM) in the first European markets, making the new treatment
available to alcohol dependent patients in Norway, Finland, Poland and the
Baltic countries. The launch marks the first introduction of a new treatment for
alcohol dependence in Europe for more than a decade. Lundbeck will continue the
rollout of Selincro in Europe through 2013 and into 2014.

According to the terms of the license agreement between Biotie and Lundbeck for
Selincro, Biotie is eligible for milestone payments upon commercial launch of
Selincro in France, Germany, Italy, Spain, and the United Kingdom, some of which
may occur in 2013; royalties on sales in all launched markets, which are not
expected to give rise to significant revenue in 2013; and a potential
contribution to Lundbeck towards any required post approval commitments studies,
which are not expected to be significant in 2013.

Turku, 22 April 2013

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Timo Veromaa President and CEO
tel. +358 2274 8900, email: timo.veromaa@biotie.com

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

www.biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd

Main Media

ABOUT SELINCRO (nalmefene):

Selincro is indicated for the reduction of alcohol consumption in adult patients
with alcohol dependence who have a high drinking risk level (>60 g/day for men,>40 g/day for women) without physical withdrawal symptoms and who do not require
immediate detoxification. Selincro should be prescribed in conjunction with
continuous psychosocial support focused on treatment adherence and the reduction
of alcohol consumption. Treatment should be initiated only in patients who
continue to have a high drinking risk level two weeks after an initial
assessment. Selincro is to be taken as-needed; that is, on each day the patient
perceives a risk of drinking alcohol, one tablet should be taken, preferably
1-2 hours prior to the anticipated time of drinking.

Biotie has licensed global rights to Selincroto Lundbeck. Under the terms of the
agreement, Biotie is eligible for up to EUR 89 million in upfront and milestone
payments plus royalties on sales of Selincro. Biotie has previously received EUR
12 million of such milestone payments from Lundbeck. Further milestone payments
are expected on commercial launch of Selincro in France, Germany, Italy, Spain,
and the United Kingdom and on the product potentially reaching certain
predetermined sales. Lundbeck is responsible for the registration, manufacturing
and marketing of the product.

ABOUT BIOTIE

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease,
Alzheimer's disease and other cognitive disorders, alcohol and drug dependence
(addiction) and post-traumatic stress disorder), and inflammatory and fibrotic
liver disease. The company has a strong and balanced development portfolio with
several innovative small molecule and biological drug candidates at different
stages of clinical development. Biotie's products address diseases with high
unmet medical need and significant market potential.

Biotie's most advanced product, Selincro (nalmefene), licensed to H. Lundbeck
A/S, has on 28 February 2013 received European marketing authorization for the
reduction of alcohol consumption in adult patients with alcohol dependence who
have a high level of alcohol consumption. In addition, Biotie has a strategic
collaboration with UCB Pharma S.A. covering tozadenant which is transitioning
into Phase 3 development for Parkinson's disease. Biotie shares are listed on
NASDAQ OMX Helsinki Ltd.


[HUG#1694693]